A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination with Standard of Care in Participants with Newly Diagnosed Multiple Myeloma (DREAMM-9)

Project: Research

NMA HREC Reference Number: SVHM HREC 228/20
NMA SSA Reference Number: SSA/68996/MonH-2021-251023(v2)
Monash Health Reference: RES-21-0000-007X

Status	Finished
Effective start/end date	1/02/21 → 31/01/26

Project Details